rap-219
·Code: RAP-219
rap-219: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Rapport Therapeutics, Inc. (RAPP) | Phase 3 |
Clinical Trials (1)
A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
FDA Decisions
FDA_MeetingRapport plans to hold an end-of-Phase 2 meeting with the U.S. Food and Drug Administration in the fourth quarter of 2025.(RAPP)
Frequently asked questions
Who is developing rap-219?
rap-219 is being developed by Rapport Therapeutics, Inc..
How many clinical trials involve rap-219?
BioSniper tracks 1 clinical trial involving rap-219.
What is rap-219's latest FDA decision?
The most recent tracked FDA decision for rap-219 is FDA_Meeting for Rapport plans to hold an end-of-Phase 2 meeting with the U.S. Food and Drug Administration in the fourth quarter of 2025..
Get deeper analysis on rap-219
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis